Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Manon KisselIsabelle Martel-LafayJustine LequesneJean-Christophe FaivreCécile Le PéchouxDinu StefanVictor BarrauxCédric LoiseauJean-Michel GrellardSerge DanhierDelphine LerougeChristos ChouaidRadj GervaisJuliette ThariatPublished in: BMC cancer (2019)
The oligometastatic spectrum is a strong prognosticator in patients undergoing SBRT for extracranial metastases. Median survival was over two years but dPFS was about 6 months. Continuation of systemic therapy in oligoprogressive patients should be investigated.
Keyphrases
- patients undergoing
- end stage renal disease
- radiation therapy
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- small cell lung cancer
- locally advanced
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- high resolution
- bone marrow
- atomic force microscopy
- rectal cancer
- smoking cessation
- high speed
- middle cerebral artery